MedPath

TRELEGY ELLIPTA

TRELEGY ELLIPTA

Approved
DIN Number

02515776

Drug Class

Human

Market Date

Sep 13, 2021

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02515776
AIG Number0360150002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE
Product Specifications
Dosage FormPowder
Route of AdministrationInhalation
AHFS Classification12:12.08.12
Health Canada Classification

ACTIVE INGREDIENTS (3)

FLUTICASONE FUROATEActive
Strength: 200 MCG / ACT
Monograph: FLUTICASONE FUROATE
UMECLIDINIUM (UMECLIDINIUM BROMIDE)Active
Strength: 62.5 MCG / ACT
Monograph: UMECLIDINIUM (UMECLIDINIUM BROMIDE)
VILANTEROL (VILANTEROL TRIFENATATE)Active
Strength: 25 MCG / ACT
Monograph: VILANTEROL (VILANTEROL TRIFENATATE)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.